Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting

Autor: Adrián Alegre, Mercedes Gironella, Fernando Escalante, Juan M. Bergua, Carmen Martínez‐Chamorro, Aurelio López, Esther González, Abelardo Bárez, Nieves Somolinos, Ernesto P. Persona, Alexia S. Cabrera, Alfons Soler, Belén I. Rodríguez, Joaquín M. López, Yolanda González, Verónica C. Giménez, Antonia Sampol, Carolina Muñoz, David Vilanova, Marta Durán, Carlos Fernández de Larrea, Spanish Myeloma Group (GEM_PETHEMA)

Publikováno v: HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)

Abstract Recommendations regarding the best time to start treatment in patients with relapsed/refractory multiple myeloma (RRMM) after biological relapse/progression (BR) are unclear. This observational, prospective, multicenter registry aimed to eva

Externí odkaz: https://doaj.org/article/93a4ae9108d049fa97aadb08fd5697cd

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Autor: Cristina Encinas, José-Ángel Hernandez-Rivas, Albert Oriol, Laura Rosiñol, María-Jesús Blanchard, José-María Bellón, Ramón García-Sanz, Javier de la Rubia, Ana López de la Guía, Ana Jímenez-Ubieto, Isidro Jarque, Belén Iñigo, Victoria Dourdil, Felipe de Arriba, Clara Cuéllar Pérez-Ávila, Yolanda Gonzalez, Miguel-Teodoro Hernández, Joan Bargay, Miguel Granell, Paula Rodríguez-Otero, Maialen Silvent, Carmen Cabrera, Rafael Rios, Adrián Alegre, Mercedes Gironella, Marta-Sonia Gonzalez, Anna Sureda, Antonia Sampol, Enrique M. Ocio, Isabel Krsnik, Antonio García, Aránzazu García-Mateo, Joan-Alfons Soler, Jesús Martín, José-María Arguiñano, María-Victoria Mateos, Joan Bladé, Jesús F. San-Miguel, Juan-José Lahuerta, Joaquín Martínez-López, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group

Publikováno v: Blood Cancer Journal, Vol 12, Iss 4, Pp 1-8 (2022)

Abstract Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would

Externí odkaz: https://doaj.org/article/fcb4c3d2e7254e4d93afeee7eb8db18a

Pseudothrombocytopenia, beyond a laboratory phenomenon: study of 192 cases

Autor: Núria Pujol-Moix, Eduardo Muñiz-Díaz, Ignacio Español, Sergi Mojal, Alfons Soler, Juan Carlos Souto

Publikováno v: Annals of Hematology. 102:1363-1374

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1074dc7ce221efe31c47ca0b91488bb7
https://doi.org/10.1007/s00277-023-05192-8

Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma

Autor: Eugenia Abella, Laura Rosiñol, Mercedes Gironella, Alicia Senín, Carlos Fernández de Larrea, Alfons Soler, Cristina Motlló, Randa Ben-Azaiz, MT Cibeira, Jordi López-Pardo, Rodrigo Martino, Marta Canet, Josep Ma Martí, Jorge Sierra, Miquel Granell, Albert Oriol, Anna Barata, Antoni Garcia-Guiñon

Publikováno v: BONE MARROW TRANSPLANTATION
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Return to work (RTW) is a marker of functional recovery in cancer patients, with quality of life, financial and social implications. We investigated frequency and factors associated with RTW in a cohort of patients younger than 66 years, with newly d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cdcab6f70a757abd5c5d6be054c8262
https://doi.org/10.1038/s41409-021-01429-0

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

Autor: David F. Moreno, Victoria Clapés, Juan Alfons Soler, Yolanda González-Montes, Mercedes Gironella, Cristina Motlló, Miquel Granell, Eugenia Abella, Marta García-Pintos, Antoni García-Guiñón, Elena Cabezudo, Joan Bladé, Laura Rosiñol

Publikováno v: Clinical Lymphoma Myeloma & Leukemia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Introduction: Daratumumab is an anti-CD38 agent that was first investigated as single agent in GEN501 and SIRIUS trials in patients with advanced multiple myeloma (MM). Overall response rate (ORR) was 30% with positive impact on progression-free surv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f05bd78bc8fc61b502d6acd72ea33bbe
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12297